Ion Beam Applications SA IBA (0GZK) Price & Analysis
0GZK Stock Chart & Stats
- Day’s Range
- EUR 16.02 - EUR 16.54
- 52-Week Range
- EUR 9.91 - EUR 17.72
- Previous Close
- EUR 16.54
- Volume
- 661
- Average Volume (3M)
- 1,255
- Market Cap
- EUR 475.22M
- Enterprise Value
- EUR 587.06M
- Total Cash (Recent Filing)
- EUR 72.40M
- Total Debt (Recent Filing)
- EUR 43.70M
- Price to Earnings (P/E)
- 19.3
- Beta
- 0.88
- Next Earnings
- Mar 25, 2027
- EPS Estimate
- 0.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.56%
0GZK FAQ
What was Ion Beam Applications SA IBA’s price range in the past 12 months?
What is Ion Beam Applications SA IBA’s market cap?
When is Ion Beam Applications SA IBA’s upcoming earnings report date?
How were Ion Beam Applications SA IBA’s earnings last quarter?
Is Ion Beam Applications SA IBA overvalued?
Does Ion Beam Applications SA IBA pay dividends?
What is Ion Beam Applications SA IBA’s EPS estimate?
How many shares outstanding does Ion Beam Applications SA IBA have?
What happened to Ion Beam Applications SA IBA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Ion Beam Applications SA IBA?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Ion Beam Applications SA IBA
Ion Beam Applications S.A. (IBA) specializes in the creation, production, and maintenance of advanced medical equipment and software systems designed to combat cancer, operating across Belgium, the United States, and numerous other countries. Its operations are structured into two key divisions: Proton Therapy and Other Accelerators, and Dosimetry. The Proton Therapy and Other Accelerators segment is dedicated to the engineering, manufacturing, and upkeep of both clinical and industrial particle accelerators, including cutting-edge proton therapy apparatus. This division also furnishes comprehensive, ready-to-use systems for treating cancer with proton beams, a range of cyclotrons crucial for generating radioisotopes for PET and SPECT imaging, as well as industrial accelerators employed in sterilization and ionization processes. The Dosimetry segment offers instruments and expertise aimed at improving the precision and reducing errors in radiation therapy, medical imaging quality assurance, and calibration. IBA maintains a crucial research and development alliance with the Belgian nuclear research center, SCK CEN, to facilitate the development of Actinium-225 (225Ac), an innovative radioisotope with potential in cancer therapy, and collaborates with the University of Pennsylvania on pioneering research into ConformalFLASH technology. Established in 1986, the company's headquarters are located in Louvain-la-Neuve, Belgium.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Olivier Legrain
- Employees
- 2,264
- Website
- www.iba-worldwide.com
- Address
- 3, Chemin du Cyclotron, Louvain-la-Neuve, BU, 1348, BE
Ion Beam Applications SA IBA (0GZK) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 5 | 6 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 7 | 0 | 5 |